• Japanese
  • Korean
  • Chinese
Cover Image

Competitive Handbook towards Personalized Medicine in Prostate Cancer

Abstract

Personalized medicine is very much about fitting target profiles of drugs towards disease mechanism(s). This report is a new and unique way of stratifying and analyzing the global prostate cancer pipeline towards personalized medicine and presents actionable analysis which allows you to discover:

  • Where the competition is; Which targets, compound types and companies are setting the path?
  • How much R&D effort has gone towards different targets and what is known about the target?
  • Which pathways are targeted, by what and how?
  • What is truly new and unique in the prostate cancer pipeline?
  • How new and unique your target strategy really is
  • What overlapping competition you have from other companies and compound types towards your therapeutic targets
  • Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

BioSeeker builds its analysis on a comprehensive base of 394 prostate cancer drugs from within the portfolio of 222 companies world-wide, from Ceased to Marketed. We have identified 227 drug targets, which we have organized into 216 drug target strategies, and assessed them by four levels:

  • 1. Individual Target: Shows you how individual targets tie into different target strategies and their subsequent R&D progress.
  • 2. Developmental Stage: Shows you the progress and maturation of different target strategies. Identifies which target strategies are new and unique from one developmental stage to the next.
  • 3. Compound Type: Shows you the competitive landscape of target strategies from a compound perspective, including crossover analysis of target strategies among different compound types.
  • 4. Company: Provides a cross-examination of each company's entire pipeline on the basis of its defined drug target strategies, including a Competitive Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.

Our Analysis includes:

  • Head-to-head target competing analysis
  • Significant drug target overlap analysis
  • Cross-sectional R&D profiling of individual drug targets.
  • Cross-over analysis of target strategies among different compound types.
  • Competitive Fall-Out analysis of the entire company pipeline: Answering three core questions about each company's pipeline:
    • Where are we?
    • Where is our general and specific competition?
    • What is the level of competition where we want to be?
    • 15 parameter deep corporate pipeline ranking, including both internal and external pipeline factors.

The report serves as an external commercial advocate for your company's interest in the prostate cancer pipeline by:

  • Better identifying benchmarking peers
  • Providing rationale for in/out licensing decisions of drug candidates
  • Performing proper drug due diligence
  • Strategies for commercial planning
  • Guiding Research & Development efforts

Table of Contents

1. Executive Summary

2. About Cancer Highlights™

  • 2.1. Cancer Focus Areas
  • 2.2. Subscribe Today and Start Saving
    • 2.2.1. Type of License
  • 2.3. Additional Information
  • 2.4. BioSeeker Group's Oncology Team

3. Methodology

  • 3.1. Cancer Highlights'™ Five Pillar Drug Assessment

4. Table of Contents

  • 4.1. List of Figures
  • 4.2. List of Tables

5. Introduction

  • 5.1. The Scope of this Report
  • 5.2. Definitions
  • 5.3. Abbreviations

6. Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment

  • 6.1. Drug Repositioning in Oncology
  • 6.2. Introduction to Targets of Prostate Cancer Drugs
    • 6.2.1. Acid Phosphatase Activity Targets
    • 6.2.2. Auxiliary Transport Protein Activity Targets
    • 6.2.3. Calcium Ion Binding Targets
    • 6.2.4. Carboxy-lyase Activity Targets
    • 6.2.5. Carboxypeptidase Activity Targets
    • 6.2.6. Catalytic Activity Targets
    • 6.2.7. Cell Adhesion Molecule Activity Targets
    • 6.2.8. Chaperone Activity Targets
    • 6.2.9. Chemokine Activity Targets
    • 6.2.10. Complement Activity Targets
    • 6.2.11. Cysteine-type Peptidase Activity Targets
    • 6.2.12. Cytokine Activity Targets
    • 6.2.13. DNA Binding Targets
    • 6.2.14. DNA Repair Protein Targets
    • 6.2.15. DNA Topoisomerase Activity Targets
    • 6.2.16. DNA-directed DNA Polymerase Activity Targets
    • 6.2.17. Extracellular Ligand-gated Ion Channel Activity Targets
    • 6.2.18. Extracellular Matrix Structural Constituent Targets
    • 6.2.19. G-protein Coupled Receptor Activity Targets
    • 6.2.20. Growth Factor Activity Targets
    • 6.2.21. GTPase Activator Activity Targets
    • 6.2.22. Hormone Activity Targets
    • 6.2.23. Hydrolase Activity Targets
    • 6.2.24. Intracellular Ligand-gated Ion Channel Activity Targets
    • 6.2.25. Ion Channel Activity Targets
    • 6.2.26. Isomerase Activity Targets
    • 6.2.27. Kinase Activity Targets
    • 6.2.28. Ligand-dependent Nuclear Receptor Activity Targets
    • 6.2.29. Ligase Activity Targets
    • 6.2.30. Lipid Kinase Activity Targets
    • 6.2.31. Lipid Phosphatase Activity Targets
    • 6.2.32. Metallopeptidase Activity Targets
    • 6.2.33. MHC Class I Receptor Activity Targets
    • 6.2.34. Molecular Function Unknown Targets
    • 6.2.35. Motor Activity Targets
    • 6.2.36. Oxidoreductase Activity Targets
    • 6.2.37. Peptidase Activity Targets
    • 6.2.38. Peptide Hormone Targets
    • 6.2.39. Peroxidase Activity Targets
    • 6.2.40. Phosphoric Diester Hydrolase Activity Targets
    • 6.2.41. Protein Binding Targets
    • 6.2.42. Protein Serine/Threonine Kinase Activity Targets
    • 6.2.43. Protein Tyrosine Phosphatase Activity Targets
    • 6.2.44. Protein-tyrosine Kinase Activity Targets
    • 6.2.45. Receptor Activity Targets
    • 6.2.46. Receptor Binding Targets
    • 6.2.47. Receptor Signaling Complex Scaffold Activity Targets
    • 6.2.48. Receptor Signaling Protein Serine/Threonine Kinase Activity Targets
    • 6.2.49. RNA Binding Targets
    • 6.2.50. RNA-directed DNA Polymerase Activity Targets
    • 6.2.51. Serine-type Peptidase Activity Targets
    • 6.2.52. Structural Constituent of Cytoskeleton Targets
    • 6.2.53. Superoxide Dismutase Activity Targets
    • 6.2.54. Transcription Factor Activity Targets
    • 6.2.55. Transcription Regulator Activity Targets
    • 6.2.56. Transferase Activity Targets
    • 6.2.57. Translation Regulator Activity Targets
    • 6.2.58. Transmembrane Receptor Activity Targets
    • 6.2.59. Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
    • 6.2.60. Transporter Activity Targets
    • 6.2.61. Ubiquitin-specific Protease Activity Targets
    • 6.2.62. Voltage-gated Ion Channel Activity Targets
    • 6.2.63. Other Targets
  • 6.3. Mutation Profiles of Prostate Cancer Drug Targets
    • 6.3.1. Targets of Prostate Cancer Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
  • 6.4. Prostate Cancer Therapeutics is Stimulated by Available Structure Data on Targets
  • 6.5. Target-Target Interactions among Identified Targets of Prostate Cancer Drugs
  • 6.6. The Drug-Target Competitive Landscape
  • 6.7. Protein Expression Levels of Identified Targets of Prostate Cancer Drugs
  • 6.8. Pathway Assessment of Prostate Cancer Drugs
    • 6.8.1. Tools for Analysis of Cancer Pathways
    • 6.8.2. Pathway Assessment

7. Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development

  • 7.1. Pre-registrered and Marketed: New and Unique Drug Target Strategies of Prostate Cancer Drugs
  • 7.2. Phase III Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Drugs
  • 7.3. Phase II Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Drugs
  • 7.4. Phase I Clinical Development: New and Unique Drug Target Strategies of Prostate Cancer Drugs
  • 7.5. Preclinical Development: New and Unique Drug Target Strategies of Prostate Cancer Drugs
  • 7.6. Drug Target Strategies of Suspended or Terminated Prostate Cancer Drugs
  • 7.7. Target Strategy Development Profiles of Prostate Cancer Drugs
    • 7.7.1. Marketed
    • 7.7.2. Pre-registration
    • 7.7.3. Phase III
    • 7.7.4. Phase II
    • 7.7.5. Phase I
    • 7.7.6. Preclinical
    • 7.7.7. No Data
    • 7.7.8. Suspended
    • 7.7.9. Ceased
  • 7.8. The Competition Through Close Mechanistic Approximation of Prostate Cancer Drugs

8. Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy

  • 8.1. Small Molecules
    • 8.1.1. Background
    • 8.1.2. Target Strategies of Small Molecule Drugs
  • 8.2. Peptide & Protein Drugs
    • 8.2.1. Background
    • 8.2.2. Target Strategies of Peptide and Protein Drugs
  • 8.3. Antibodies
    • 8.3.1. Background
    • 8.3.2. Target Strategies of Antibody Drugs
  • 8.4. Nucleic Acid Therapies
    • 8.4.1. Background
    • 8.4.2. Target Strategies of Nucleic Acid Drugs
  • 8.5. Cell & Gene Therapy
    • 8.5.1. Background
    • 8.5.2. Target Strategies of Cell and Gene Therapy Drugs
  • 8.6. Drug Delivery and Nanotechnology
    • 8.6.1. Background
    • 8.6.2. Target Strategies of Reformulated Drugs
  • 8.7. Compound Strategies based on Sub-Cellular Localization of Drug Targets

9. Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator

  • 9.1. Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change
  • 9.2. Company Facts and Ranking
  • 9.3. Competitive Fall-Out Assessment
  • 9.4. Abbott
  • 9.5. Active Biotech
  • 9.6. Advantagene
  • 9.7. AEgera
  • 9.8. AEterna Zentaris
  • 9.9. Alchemia
  • 9.10. Alethia Biotherapeutics
  • 9.11. Allos Therapeutics
  • 9.12. AlphaVax
  • 9.13. Alseres Pharmaceuticals
  • 9.14. Altor BioScience
  • 9.15. Ambrilia Biopharma
  • 9.16. American Gene Technology International
  • 9.17. Amgen
  • 9.18. Anavex Life Sciences
  • 9.19. AndroBioSys
  • 9.20. Antisense Pharma
  • 9.21. Antisense Therapeutics
  • 9.22. Antisoma
  • 9.23. Aphios
  • 9.24. ApopLogic Pharmaceuticals
  • 9.25. Apotex
  • 9.26. Aprea
  • 9.27. Ardana
  • 9.28. Ariad
  • 9.29. ArQule
  • 9.30. Array BioPharma
  • 9.31. Ascenta Therapeutics
  • 9.32. Ascepion Pharmaceuticals
  • 9.33. Astellas
  • 9.34. Astex Pharmaceuticals
  • 9.35. AstraZeneca
  • 9.36. Attenuon
  • 9.37. AVI BioPharma
  • 9.38. Bavarian Nordic
  • 9.39. Baxter International
  • 9.40. Bayer
  • 9.41. Bellicum Pharmaceuticals
  • 9.42. Bioenvision
  • 9.43. Biogen Idec
  • 9.44. BioLineRx
  • 9.45. BioMarin
  • 9.46. BioNetWorks
  • 9.47. BioSante
  • 9.48. Biostar
  • 9.49. Boehringer Ingelheim
  • 9.50. Bristol-Myers Squibb
  • 9.51. BTG
  • 9.52. Camurus
  • 9.53. Cancer Research Technology
  • 9.54. Cel-Sci
  • 9.55. Celgene
  • 9.56. Cell Therapeutics
  • 9.57. Celldex Therapeutics
  • 9.58. Celsion
  • 9.59. Center of Molecular Immunology
  • 9.60. Cephalon
  • 9.61. Chemokine Therapeutics
  • 9.62. Circadian Technologies
  • 9.63. Cleveland BioLabs
  • 9.64. Colby
  • 9.65. Cosmo Bioscience
  • 9.66. Curaxis
  • 9.67. Curis
  • 9.68. Cylene Pharmaceuticals
  • 9.69. Cytokinetics
  • 9.70. Daiichi Sankyo
  • 9.71. Debiopharm
  • 9.72. Dendreon
  • 9.73. Dongkook Pharm
  • 9.74. ECI
  • 9.75. Eisai
  • 9.76. Eli Lilly
  • 9.77. Endo Pharmaceuticals
  • 9.78. Endocyte
  • 9.79. Ensemble Discovery
  • 9.80. EntreMed
  • 9.81. EpiCept
  • 9.82. Esperance Pharmaceuticals
  • 9.83. Etubics
  • 9.84. EUSA Pharma
  • 9.85. Exelixis
  • 9.86. Ferring
  • 9.87. Formula Pharmaceuticals
  • 9.88. Galena Biopharma
  • 9.89. Gemin X Pharmaceuticals
  • 9.90. Generex
  • 9.91. GENova Biotherapeutics
  • 9.92. Genovax
  • 9.93. Genta
  • 9.94. Gerolymatos
  • 9.95. Geron
  • 9.96. Gilead Sciences
  • 9.97. GlaxoSmithKline
  • 9.98. GlycoGenesys
  • 9.99. Got-a-Gene
  • 9.100. GP Pharm
  • 9.101. Green Cross
  • 9.102. GTx
  • 9.103. Harbor BioSciences
  • 9.104. Hoffmann-La Roche
  • 9.105. Human Genome Sciences
  • 9.106. IGF Oncology
  • 9.107. Immunocore
  • 9.108. ImmunoGen
  • 9.109. Immunomedics
  • 9.110. ImmuPharma
  • 9.111. Incyte Corporation
  • 9.112. Infinity Pharmaceuticals
  • 9.113. Inovio
  • 9.114. Insmed
  • 9.115. Insys Therapeutics
  • 9.116. Introgen Therapeutics
  • 9.117. Ipsen
  • 9.118. Isis Pharmaceuticals
  • 9.119. Ivy Medical Chemicals
  • 9.120. Johnson & Johnson
  • 9.121. Karo Bio
  • 9.122. Kinex
  • 9.123. Kyowa Hakko Kirin
  • 9.124. Leo
  • 9.125. Ligand
  • 9.126. Lorus Therapeutics
  • 9.127. Mannkind
  • 9.128. Marillion Pharmaceuticals
  • 9.129. Med Discovery
  • 9.130. Meda
  • 9.131. Medarex
  • 9.132. MediGene
  • 9.133. MedImmune
  • 9.134. Mediolanum
  • 9.135. Medivation
  • 9.136. Menarini
  • 9.137. Merck & Co
  • 9.138. Merck KGaA
  • 9.139. Merrion Pharmaceuticals
  • 9.140. MethylGene
  • 9.141. Mojave Therapeutics
  • 9.142. Molecular Insight
  • 9.143. Nektar Therapeutics
  • 9.144. Nereus Pharmaceuticals
  • 9.145. Nerviano Medical Sciences
  • 9.146. Neurocrine Biosciences
  • 9.147. Nippon Shinyaku
  • 9.148. Non-industrial Sources
  • 9.149. Northwest Biotherapeutics
  • 9.150. Novacea
  • 9.151. Novartis
  • 9.152. Novogen
  • 9.153. Oasmia
  • 9.154. OncoGenex Pharmaceuticals
  • 9.155. Oncothyreon
  • 9.156. Oncovir
  • 9.157. Orion Pharma
  • 9.158. OSI Pharmaceuticals
  • 9.159. Oxford BioMedica
  • 9.160. Paladin Labs
  • 9.161. Pantarhei Bioscience
  • 9.162. Pepscan Therapeutics
  • 9.163. Pfizer
  • 9.164. Pharmacyclics
  • 9.165. PharmaGap
  • 9.166. PharmaMar
  • 9.167. Philogen
  • 9.168. Pierre Fabre
  • 9.169. Progen
  • 9.170. Progenics Pharmaceuticals
  • 9.171. ProNAi Therapeutics
  • 9.172. ProStrakan
  • 9.173. Q Chip
  • 9.174. QLT
  • 9.175. Receptor BioLogix
  • 9.176. Regeneron
  • 9.177. Regulon
  • 9.178. Rexahn
  • 9.179. Salzburg Therapeutics
  • 9.180. Samyang
  • 9.181. Sanofi
  • 9.182. Santaris Pharma
  • 9.183. Sapphire Therapeutics
  • 9.184. SBIO
  • 9.185. SeleXel
  • 9.186. Semafore Pharmaceuticals
  • 9.187. Serometrix
  • 9.188. SGX Pharmaceuticals
  • 9.189. Shire
  • 9.190. Siena Biotech
  • 9.191. Soligenix
  • 9.192. Sophiris Bio
  • 9.193. SRI International
  • 9.194. Supratek Pharma
  • 9.195. Switch Pharma
  • 9.196. Synta Pharmaceuticals
  • 9.197. Taiho
  • 9.198. Takeda
  • 9.199. Tapestry Pharmaceuticals
  • 9.200. Tau Therapeutics
  • 9.201. Teva
  • 9.202. Thallion Pharmaceuticals
  • 9.203. Therion Biologics
  • 9.204. Titan Pharmaceuticals
  • 9.205. Tokai Pharmaceuticals
  • 9.206. TopoTarget
  • 9.207. Tracon Pharmaceuticals
  • 9.208. Transgene
  • 9.209. Twinstrand Therapeutics
  • 9.210. Unigene
  • 9.211. United Biomedical
  • 9.212. Vaxon Biotech
  • 9.213. Velacor Therapeutics
  • 9.214. Vical
  • 9.215. Vion Pharmaceuticals
  • 9.216. VioQuest
  • 9.217. Viralytics
  • 9.218. ViroTarg
  • 9.219. VM Discovery
  • 9.220. Wilex
  • 9.221. Xerion
  • 9.222. Xoma
  • 9.223. YM BioSciences
  • 9.224. Zydus Cadila

10. Disclaimer

11. Drug Index

12. Company Index

List of Figures

  • Figure 1: Visualization of Target-Target Interactions among Targets of Prostate Cancer Drugs
  • Figure 2: The Drug-Target Competitive Landscape of Prostate Cancer Drugs - Larger Clusters
  • Figure 3: The Drug-Target Competitive Landscape Prostate Cancer Drugs - Smaller Clusters
  • Figure 4: Head-to-Head Targeting Competitive Landscape of Prostate Cancer Drugs - Larger Clusters
  • Figure 5: Head-to-Head Targeting Competitive Landscape of Prostate Cancer Drugs - Smaller Clusters
  • Figure 6: Distribution of Compound Strategies among Prostate Cancer Drugs
  • Figure 7: Primary Sub-cellular Localization of Drug Targets
  • Figure 8: Number of Companies per Ranking Level

List of Tables

  • Table 1: Cancer Highlights'™ Five Pillar Drug Assessment
  • Table 2: Breakdown of the Included Prostate Cancer Drug Pipeline by Stage of Development
  • Table 3: Head to Head Target Competition among Prostate Cancer Drugs
  • Table 4: Overview of Drug Target Strategy Themes
  • Table 5: Terminally Ceased Targets of Prostate Cancer Drugs
  • Table 6: Official Gene Symbol to Target Profle
  • Table 7: Mutation Frequencies of Prostate Cancer Drug Targets
  • Table 8: Identity of Drug Targets with Available Biological Structures
  • Table 9: Number of Target-Target Interactions among Targets of Prostate Cancer Drugs
  • Table 10: Available Protein Expression Profiles of Prostate Cancer Drug Targets
  • Table 11: Pathway Summary
  • Table 12: Drug Targets without any Identified Assigned Pathways
  • Table 13: Pathway Profiles According to BioCarta of Prostate Cancer Drug Targets
  • Table 14: Pathway Profiles According to KEGG of Prostate Cancer Drug Targets
  • Table 15: Pathway Profiles According to NetPath of Prostate Cancer Drug Targets
  • Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness
  • Table 17: Top Competitive Target Strategies of Prostate Cancer Drugs
  • Table 18: New and Unique Target Strategies of Prostate Cancer Drugs in Pre-registration or on the Marketed
  • Table 19: The Competition Through Close Mechanistic Approximation Between Prostate Cancer Drugs Being Marketed
  • Table 20: New and Unique Target Strategies in Phase III Clinical Development of Prostate Cancer Drugs
  • Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Prostate Cancer Drugs
  • Table 22: New and Unique Target Strategies in Phase II Clinical Development of Prostate Cancer Drugs
  • Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Prostate Cancer Drugs
  • Table 24: New and Unique Target Strategies in Phase I Clinical Development of Prostate Cancer Drugs
  • Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Prostate Cancer Drugs
  • Table 26: New and Unique Target Strategies in Preclinical Development of Prostate Cancer Drugs
  • Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Prostate Cancer Drugs
  • Table 28: Target Strategies of No Data, Suspended or Terminated Prostate Cancer Drugs
  • Table 29: Connecting Target Strategy with Its Profile Identification Number
  • Table 30: The Competition Through Close Mechanistic Approximation Among Prostate Cancer Drugs
  • Table 31: Overview of Compound Strategy Competition Among Prostate Cancer Drugs
  • Table 32: Overview of the Competitive Landscape of Small Molecule Based Prostate Cancer Drugs
  • Table 33: Competitive Comparison of Target Strategies of Small Molecule Prostate Cancer Drugs
  • Table 34: Pursued Target Strategies of Small Molecule Drugs Based Prostate Cancer Drugs
  • Table 35: Overview of the Competitive Landscape of Peptide Based Prostate Cancer Drugs
  • Table 36: Competitive Comparison of Target Strategies of Peptide Based Prostate Cancer Drugs
  • Table 37: Pursued Target Strategies of Peptide Based Prostate Cancer Drugs
  • Table 38: Overview of the Competitive Landscape of Protein Based Prostate Cancer Drugs
  • Table 39: Competitive Comparison of Target Strategies of Protein Based Prostate Cancer Drugs
  • Table 40: Pursued Target Strategies of Protein Based Prostate Cancer Drugs
  • Table 41: Overview of the Competitive Landscape of Antibody Based Prostate Cancer Drugs
  • Table 42: Competitive Comparison of Target Strategies of Antibody Based Prostate Cancer Drugs
  • Table 43: Pursued Target Strategies of Antibody Based Prostate Cancer Drugs
  • Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Prostate Cancer Drugs
  • Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Prostate Cancer Drugs
  • Table 46: Pursued Target Strategies of Nucleic Acid Based Prostate Cancer Drugs
  • Table 47: Potential Forms of Cell Therapy
  • Table 48: Vectors in Gene Therapy
  • Table 49: Overview of the Competitive Landscape of Cell Therapy Based Prostate Cancer Drugs
  • Table 50: Competitive Comparison of Target Strategies of Cell Therapy Based Prostate Cancer Drugs
  • Table 51: Pursued Target Strategies of Cell Therapy Based Prostate Cancer Drugs
  • Table 52: Overview of the Competitive Landscape of Gene Therapy Based Prostate Cancer Drugs
  • Table 53: Competitive Comparison of Target Strategies of Gene Therapy Based Prostate Cancer Drugs
  • Table 54: Pursued Target Strategies of Gene Therapy Based Prostate Cancer Drugs
  • Table 55:Overview of the Competitive Landscape of Reformulated Prostate Cancer Drugs
  • Table 56: Competitive Comparison of Target Strategies of Reformulated Prostate Cancer Drugs
  • Table 57: Pursued Target Strategies of Reformulated Prostate Cancer Drugs
  • Table 58: Compound Strategies based on Sub-Cellular Localization of Prostate Cancer Drug Targets
  • Table 59: Competitive Summary by Investigator of Prostate Cancer Drug Development
  • Table 60: Summary Table of Corporate Changes in the Competitive Landscape of Prostate Cancer Drug Development
  • Table 61: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters
  • Table 62: Example of a Competitive Fall-Out Table (Targeting TOP2A)
  • Table 63: Abbott's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 64: Active Biotech's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 65: Advantagene's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 66: AEgera's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 67: AEterna Zentaris' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 68: Alchemia's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 69: Alethia Biotherapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 70: Allos Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 71: AlphaVax's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 72: Alseres Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 73: Altor BioScience's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 74: Ambrilia Biopharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 75: American Gene Technology International's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 76: Amgen's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 77: Anavex Life Sciences' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 78: AndroBioSys' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 79: Antisense Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 80: Antisense Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 81: Antisoma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 82: Aphios' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 83: ApopLogic Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 84: Apotex's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 85: Aprea's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 86: Ardana's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 87: Ariad's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 88: ArQule's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 89: Array BioPharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 90: Ascenta Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 91: Ascepion Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 92: Astellas' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 93: Astex Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 94: AstraZeneca's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 95: Attenuon's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 96: AVI BioPharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 97: Bavarian Nordic's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 98: Baxter International's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 99: Bayer's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 100: Bellicum Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 101: Bioenvision's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 102: Biogen Idec's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 103: BioLineRx's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 104: BioMarin's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 105: BioNetWorks' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 106: BioSante's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 107: Biostar's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 108: Boehringer Ingelheim's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 109: Bristol-Myers Squibb's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 110: BTG's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 111: Camurus' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 112: Cancer Research Technology's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 113: Cel-Sci's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 114: Celgene's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 115: Cell Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 116: Celldex Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 117: Celsion's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 118: Center of Molecular Immunology's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 119: Cephalon's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 120: Chemokine Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 121: Circadian Technologies' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 122: Cleveland BioLabs' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 123: Colby's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 124: Cosmo Bioscience's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 125: Curaxis' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 126: Curis' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 127: Cylene Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 128: Cytokinetics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 129: Daiichi Sankyo's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 130: Debiopharm's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 131: Dendreon's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 132: Dongkook Pharm's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 133: ECI's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 134: Eisai's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 135: Eli Lilly's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 136: Endo Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 137: Endocyte's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 138: Ensemble Discovery's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 139: EntreMed's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 140: EpiCept's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 141: Esperance Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 142: Etubics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 143: EUSA Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 144: Exelixis' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 145: Ferring's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 146: Formula Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 147: Galena Biopharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 148: Gemin X Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 149: Generex's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 150: GENova Biotherapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 151: Genovax's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 152: Genta's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 153: Gerolymatos' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 154: Geron's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 155: Gilead Sciences' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 156: GlaxoSmithKline's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 157: GlycoGenesys' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 158: Got-a-Gene's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 159: GP Pharm's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 160: Green Cross' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 161: GTx's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 162: Harbor BioSciences' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 163: Hoffmann-La Roche's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 164: Human Genome Sciences' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 165: IGF Oncology's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 166: Immunocore's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 167: ImmunoGen's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 168: Immunomedics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 169: ImmuPharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 170: Incyte Corporation's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 171: Infinity Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 172: Inovio's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 173: Insmed's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 174: Insys Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 175: Introgen Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 176: Ipsen's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 177: Isis Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 178: Ivy Medical Chemicals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 179: Johnson & Johnson's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 180: Karo Bio's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 181: Kinex's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 182: Kyowa Hakko Kirin's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 183: Leo's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 184: Ligand's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 185: Lorus Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 186: Mannkind's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 187: Marillion Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 188: Med Discovery's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 189: Meda's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 190: Medarex's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 191: MediGene's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 192: MedImmune's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 193: Mediolanum's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 194: Medivation's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 195: Menarini's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 196: Merck & Co's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 197: Merck KGaA's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 198: Merrion Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 199: MethylGene's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 200: Mojave Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 201: Molecular Insight's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 202: Nektar Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 203: Nereus Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 204: Nerviano Medical Sciences' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 205: Neurocrine Biosciences' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 206: Nippon Shinyaku's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 207: Non-industrial source's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 208: Northwest Biotherapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 209: Novacea's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 210: Novartis' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 211: Novogen's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 212: Oasmia's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 213: OncoGenex Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 214: Oncothyreon's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 215: Oncovir's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 216: Orion Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 217: OSI Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 218: Oxford BioMedica's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 219: Paladin Labs' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 220: Pantarhei Bioscience's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 221: Pepscan Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 222: Pfizer's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 223: Pharmacyclics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 224: PharmaGap's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 225: PharmaMar's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 226: Philogen's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 227: Pierre Fabre's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 228: Progen's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 229: Progenics Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 230: ProNAi Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 231: ProStrakan's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 232: Q Chip's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 233: QLT's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 234: Receptor BioLogix's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 235: Regeneron's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 236: Regulon's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 237: Rexahn's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 238: Salzburg Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 239: Samyang's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 240: Sanofi's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 241: Santaris Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 242: Sapphire Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 243: SBIO's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 244: SeleXel's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 245: Semafore Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 246: Serometrix's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 247: SGX Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 248: Shire's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 249: Siena Biotech's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 250: Soligenix's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 251: Sophiris Bio's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 252: SRI International's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 253: Supratek Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 254: Switch Pharma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 255: Synta Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 256: Taiho's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 257: Takeda's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 258: Tapestry Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 259: Tau Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 260: Teva's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 261: Thallion Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 262: Therion Biologics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 263: Titan Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 264: Tokai Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 265: TopoTarget's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 266: Tracon Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 267: Transgene's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 268: Twinstrand Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 269: Unigene's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 270: United Biomedical's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 271: Vaxon Biotech's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 272: Velacor Therapeutics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 273: Vical's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 274: Vion Pharmaceuticals' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 275: VioQuest's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 276: Viralytics' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 277: ViroTarg's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 278: VM Discovery's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 279: Wilex's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 280: Xerion's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 281: Xoma's Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 282: YM BioSciences' Included Prostate Cancer Drugs and Competitive Fall-Out
  • Table 283: Zydus Cadila's Included Prostate Cancer Drugs and Competitive Fall-Out

This report includes 222 companies (Incl. Active, Out of Business and M&A) plus their collaborators:

  • Abbott
  • Active Biotech
  • Advantagene
  • AEgera
  • AEterna Zentaris
  • Alchemia
  • Alethia Biotherapeutics
  • Allos Therapeutics
  • AlphaVax
  • Alseres Pharmaceuticals
  • Altor BioScience
  • Ambrilia Biopharma
  • American Gene Technology International
  • Amgen
  • Anavex Life Sciences
  • AndroBioSys
  • Antisense Pharma
  • Antisense Therapeutics
  • Antisoma
  • Aphios
  • ApopLogic Pharmaceuticals
  • Apotex
  • Aprea
  • Ardana
  • Ariad
  • ArQule
  • Array BioPharma
  • Ascenta Therapeutics
  • Ascepion Pharmaceuticals
  • Astellas
  • Astex Pharmaceuticals
  • AstraZeneca
  • Attenuon
  • AVI BioPharma
  • Bavarian Nordic
  • Baxter International
  • Bayer
  • Bellicum Pharmaceuticals
  • Bioenvision
  • Biogen Idec
  • BioLineRx
  • BioMarin
  • BioNetWorks
  • BioSante
  • Biostar
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • BTG
  • Camurus
  • Cancer Research Technology
  • Celgene
  • Cell Therapeutics
  • Celldex Therapeutics
  • Cel-Sci
  • Celsion
  • Center of Molecular Immunology
  • Cephalon
  • Chemokine Therapeutics
  • Circadian Technologies
  • Cleveland BioLabs
  • Colby
  • Cosmo Bioscience
  • Curaxis
  • Curis
  • Cylene Pharmaceuticals
  • Cytokinetics
  • Daiichi Sankyo
  • Debiopharm
  • Dendreon
  • Dongkook Pharm
  • ECI
  • Eisai
  • Eli Lilly
  • Endo Pharmaceuticals
  • Endocyte
  • Ensemble Discovery
  • EntreMed
  • EpiCept
  • Esperance Pharmaceuticals
  • Etubics
  • EUSA Pharma
  • Exelixis
  • Ferring
  • Formula Pharmaceuticals
  • Galena Biopharma
  • Gemin X Pharmaceuticals
  • Generex
  • GENova Biotherapeutics
  • Genovax
  • Genta
  • Gerolymatos
  • Geron
  • Gilead Sciences
  • GlaxoSmithKline
  • GlycoGenesys
  • Got-a-Gene
  • GP Pharm
  • Green Cross
  • GTx
  • Harbor BioSciences
  • Hoffmann-La Roche
  • Human Genome Sciences
  • IGF Oncology
  • Immunocore
  • ImmunoGen
  • Immunomedics
  • ImmuPharma
  • Incyte Corporation
  • Infinity Pharmaceuticals
  • Inovio
  • Insmed
  • Insys Therapeutics
  • Introgen Therapeutics
  • Ipsen
  • Isis Pharmaceuticals
  • Ivy Medical Chemicals
  • Johnson & Johnson
  • Karo Bio
  • Kinex
  • Kyowa Hakko Kirin
  • Leo
  • Ligand
  • Lorus Therapeutics
  • Mannkind
  • Marillion Pharmaceuticals
  • Med Discovery
  • Meda
  • Medarex
  • MediGene
  • MedImmune
  • Mediolanum
  • Medivation
  • Menarini
  • Merck & Co
  • Merck KGaA
  • Merrion Pharmaceuticals
  • MethylGene
  • Mojave Therapeutics
  • Molecular Insight
  • Nektar Therapeutics
  • Nereus Pharmaceuticals
  • Nerviano Medical Sciences
  • Neurocrine Biosciences
  • Nippon Shinyaku
  • Non-industrial source
  • Northwest Biotherapeutics
  • Novacea
  • Novartis
  • Novogen
  • Oasmia
  • OncoGenex Pharmaceuticals
  • Oncothyreon
  • Oncovir
  • Orion Pharma
  • OSI Pharmaceuticals
  • Oxford BioMedica
  • Paladin Labs
  • Pantarhei Bioscience
  • Pepscan Therapeutics
  • Pfizer
  • Pharmacyclics
  • PharmaGap
  • PharmaMar
  • Philogen
  • Pierre Fabre
  • Progen
  • Progenics Pharmaceuticals
  • ProNAi Therapeutics
  • ProStrakan
  • Q Chip
  • QLT
  • Receptor BioLogix
  • Regeneron
  • Regulon
  • Rexahn
  • Salzburg Therapeutics
  • Samyang
  • Sanofi
  • Santaris Pharma
  • Sapphire Therapeutics
  • SBIO
  • SeleXel
  • Semafore Pharmaceuticals
  • Serometrix
  • SGX Pharmaceuticals
  • Shire
  • Siena Biotech
  • Soligenix
  • Sophiris Bio
  • SRI International
  • Supratek Pharma
  • Switch Pharma
  • Synta Pharmaceuticals
  • Taiho
  • Takeda
  • Tapestry Pharmaceuticals
  • Tau Therapeutics
  • Teva
  • Thallion Pharmaceuticals
  • Therion Biologics
  • Titan Pharmaceuticals
  • Tokai Pharmaceuticals
  • TopoTarget
  • Tracon Pharmaceuticals
  • Transgene
  • Twinstrand Therapeutics
  • Unigene
  • United Biomedical
  • Vaxon Biotech
  • Velacor Therapeutics
  • Vical
  • Vion Pharmaceuticals
  • VioQuest
  • Viralytics
  • ViroTarg
  • VM Discovery
  • Wilex
  • Xerion
  • Xoma
  • YM BioSciences
  • Zydus Cadila

This report includes 394 prostate cancer drugs. From Ceased to Marketed.

Some examples are:

  • abarelix
  • abiraterone acetate
  • adecatumumab
  • aderbasib
  • AEZS-108
  • afatinib
  • aflibercept
  • ALT-801
  • alvocidib
  • amonafide dihydrochloride
  • amonafide malate
  • APC-100
  • APR-246
  • ARC-100
  • atrasentan
  • AVX-701
  • bafetinib
  • bevacizumab
  • BIBF-1120
  • bicalutamide
  • BMS-777607
  • BMS-936558
  • bortezomib
  • BP-GMAX-CD1
  • buserelin
  • Cabozantinib
  • carlumab
  • cediranib
  • celecoxib
  • cetuximab
  • cixutumumab
  • custirsen
  • danusertib
  • dasatinib
  • DCVax-prostate
  • degarelix
  • denosumab
  • deslorelin
  • DI-17E6
  • docetaxel
  • dovitinib lactate
  • doxercalciferol
  • doxorubicin
  • dutasteride
  • E-75
  • entinostat
  • enzastaurin hydrochloride
  • estramustine phosphate sodium
  • ethinyl estradiol sulfonate
  • everolimus
  • figitumumab
  • flutamide
  • fulvestrant
  • gataparsen
  • GDC-0980
  • gefitinib
  • goserelin (1)
  • GTx-758
  • GVAX
  • GVX-3322
  • GX-301
  • HE-3235
  • histrelin
  • idronoxil
  • imatinib mesilate
  • inecalcitol
  • INSM-18
  • interleukins
  • intetumumab
  • ipilimumab
  • irosustat
  • ispinesib mesylate
  • KX2-391
  • lapatinib ditosylate
  • lestaurtinib
  • leucine-doxorubicin
  • leuprolide
  • leuprolide acetate
  • leuprorelin acetate
  • LIP-131I
  • LipoVIL12
  • litronesib
  • LOR-2040
  • LOR-2501
  • LY-2275796
  • MCS-110
  • MDV-3100
  • MLN-8237
  • Nab-docetaxel
  • nadroparin
  • nilutamide
  • nimotuzumab
  • oblimersen sodium
  • OGX-427
  • olaparib
  • olaratumab
  • orteronel
  • ozarelix
  • paclitaxel
  • paclitaxel polyglumex
  • panitumumab
  • panobinostat
  • perifosine
  • pertuzumab
  • plitidepsin
  • PLX-3397
  • ProstAtak
  • PROSTVAC
  • PRX-302
  • PX-866
  • quarfloxacin
  • quinacrine
  • R-(-)-gossypol
  • ramucirumab
  • retaspimycin
  • ridaforolimus
  • rilotumumab
  • romidepsin
  • ruxolitinib
  • sagopilone
  • sargramostim
  • SB-939
  • siltuximab
  • sipuleucel-T
  • sorafenib tosylate
  • TAK-448
  • tandutinib
  • tasquinimod
  • telomerase vaccine
  • temsirolimus
  • Tenarad
  • TOK-001
  • toremifene citrate
  • TRC-105
  • tremelimumab
  • trilostane
  • triptorelin
  • TroVax
  • TS-1
  • tucotuzumab celmoleukin
  • vandetanib
  • YM-155
  • zibotentan
Show More
RELATED REPORTS
* Personalized Medicine Partnering Terms and Agreements
  • Published:
  • Apr 02, 2014
  • USD 3295

* Personalized Medicine - scientific & commercial aspects
  • Published:
  • Mar 01, 2014
  • USD 5000

* Personalized Medicine in Oncology Partnering Terms and Agreements
  • Published:
  • Jan 10, 2014
  • USD 2995
  • 833 Pages

* Personalized Medicine and Companion Diagnostic Market 2014- A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment
  • Published:
  • Jan 03, 2014
  • USD 3660
  • 224 Pages

* Cancer/Tumor Profiling Market [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics, Metabolomics, Epigenetics)] 2013 - 2018
  • Published:
  • Sep 30, 2013
  • USD 4650
  • 173 Pages

* Molecular Cytogenetics Market (Technologies: FISH and aCGH; Applications: Genetic Disorders, Cancer and Personalized Medicine) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
  • Published:
  • Aug 21, 2013
  • USD 4595
  • 96 Pages

* Global Personalized Medicine Diagnostics Market 2012-2016
  • Published:
  • Jul 26, 2013
  • USD 3000
  • 111 Pages

* Future Prospects of Global Personalized Medicine Market 2012-2016
  • Published:
  • Jul 05, 2013
  • USD 2500
  • 60 Pages

* Next Generation Sequencing (NGS) Market [Platforms (Illumina HiSeq, MiSeq, Life Technologies Ion Proton/PGM, 454 Roche), Bioinformatics (RNA-Seq, ChIP-Seq), (Pyrosequencing, SBS, SMRT), (Diagnostics, Personalized Medicine)] - Global Forecast to 2017
  • Published:
  • Jul 01, 2013
  • USD 4650
  • 350 Pages

* Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing)
  • Published:
  • Jun 13, 2013
  • USD 1400
  • 173 Pages

Browse more Personalized Medicine Market Research Reports

Pricing
Get Notified
Email me when related reports are published